Arbutus Biopharma (ABUS) Revenue (2013 - 2026)
Arbutus Biopharma (ABUS) posted Revenue of $179.1 million for Q1 2026, up 16943.39% sequentially from $1.1 million in Q4 2025, and up 10054.54% YoY from N/an in Q1 2025.
Arbutus Biopharma (ABUS) Revenue (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Revenue for 14 years, with the latest figure at $179.1 million in Q1 2026.
- Quarterly Revenue rose 10054.54% year-over-year to $179.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $191.4 million (up 2889.93% YoY) and the FY2025 annual result came in at $14.1 million, up 128.21% from the prior year.
- Revenue advanced to $179.1 million in Q1 2026 per ABUS's latest filing, from $1.1 million in the prior quarter.
- Over five years, Revenue peaked at $179.1 million in Q1 2026 and troughed at $529000.0 in Q3 2025.
- A 5-year average of $15.1 million and a median of $4.7 million in 2023 frame the typical range for Revenue.
- The sharpest annual moves came in 2024 and 2026: Revenue slumped 77.09% in 2024, then jumped 10054.54% in 2026.
- Over 5 years, Revenue stood at $6.2 million in 2022, then slumped by 65.65% to $2.1 million in 2023, then retreated by 26.62% to $1.6 million in 2024, then sank by 33.23% to $1.1 million in 2025, then jumped by 16943.39% to $179.1 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $179.1 million, $1.1 million, and $529000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 1.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 Mn |
| Mar 31, 2026 | 179.13 Mn |
| Dec 31, 2025 | 1.05 Mn |
| Sep 30, 2025 | 529,000.00 |
| Jun 30, 2025 | 10.74 Mn |
| Mar 31, 2025 | 1.76 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Dec 31, 2023 | 2.15 Mn |
| Sep 30, 2023 | 4.66 Mn |
| Jun 30, 2023 | 4.65 Mn |
| Mar 31, 2023 | 6.69 Mn |
| Dec 31, 2022 | 6.25 Mn |
| Sep 30, 2022 | 5.95 Mn |
| Jun 30, 2022 | 14.24 Mn |
| Mar 31, 2022 | 12.58 Mn |
| Dec 31, 2021 | 3.21 Mn |
| Sep 30, 2021 | 3.34 Mn |